Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...
These pathways represent potential therapeutic vulnerabilities ... The observation that phosphorylation signatures identified by KScan outperform FLT3 mutational status at predicting midostaurin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback